Celgene

Founded 1986
Founders Robert J. Hariri M.D. Ph.D. Sol Barer

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 57
Average round size
info
The average size of a deal this fund participated in
$46M
Portfolio companies 46
Rounds per year 1.63
Lead investments 11
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.26
Exits 21
Key employees 3

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 1986 was created Celgene, which is appeared as Corporate Investor. The venture was found in North America in United States. The main office of represented Corporate Investor is situated in the Summit.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Celgene, startups are often financed by Kleiner Perkins, ARCH Venture Partners, OrbiMed. The meaningful sponsors for the fund in investment in the same round are The Column Group, OUP (Osage University Partners), Kleiner Perkins. In the next rounds fund is usually obtained by The Column Group, Kleiner Perkins, GV.

This Celgene works on 2 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 deals per year. The average startup value when the investment from Celgene is 500 millions - 1 billion dollars. The increased amount of exits for fund were in 2018. The common things for fund are deals in the range of 50 - 100 millions dollars. Speaking about the real fund results, this Corporate Investor is 5 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2016. Despite it in 2019 the fund had an activity.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight NantHealth, ARMO BioSciences, Flexus Biosciences. We can highlight the next thriving fund investment areas, such as Biotechnology, Medical Device. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low.

This organization was formed by Robert Hariri, Sol Barer. We also calculated 1 valuable employee in our database.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Cyteir Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$40M15 Oct 2019 Cambridge, Massachusetts, United States

Anokion

Biotechnology
Clinical Trials
Therapeutics
$40M11 Sep 2019 Vaud, Switzerland

immatics biotechnologies

Biotechnology
Medical
Therapeutics
$75M05 Sep 2019 Germany, Baden-Württemberg, Germany

Oncorus

Biotechnology
Medical
Therapeutics
$79M21 Aug 2019 Cambridge, Massachusetts, United States

Cleave Therapeutics

Biopharma
Biotechnology
Health Care
$12M06 Aug 2019 San Francisco, California, United States

GNS Healthcare

Analytics
Big Data
Bioinformatics
Genetics
Health Care
$23M09 Jul 2019 Cambridge, Massachusetts, United States

Arrakis Therapeutics

Biopharma
Biotechnology
Medical
Pharmaceutical
$75M18 Apr 2019 Massachusetts, United States

HiberCell

Biotechnology
Health Care
Health Diagnostics
Medical
$60M07 Feb 2019 New York, United States

Biond Biologics

Biotechnology
Health Care
Pharmaceutical
$17M08 Jan 2019 North District
News
Presage Biosciences raises $13M and inks new deal with Merck for cancer drug tests

– Seattle’s Presage Biosciences announced $13m in funding.
– The funding was led by Arch Venture Partners and joined by existing investors, including Takeda Pharmaceutical, Celgene and Bristol Myers Squibb (BMS).
– The company has raised a total of $35m in equity.
– Presage is a biotech device company that has built a platform for testing new cancer drugs used to treat tumors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Celgene?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: